The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
September 19th 2024
EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.
September 12th 2024
September 10th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
What's the Story with Testosterone Replacement Therapy and Diabetes?
Just weeks after Australian researchers published data suggesting that testosterone replacement therapy does not ameliorate type 2 diabetes among hypogonadal men, a team of American researchers has unveiled a second study that suggests just the opposite.
Aggressive Management of Obesity and Other Atrial Fibrillation Risk Factors
A new study indicates that treating hyperlipidemia, glucose intolerance, high blood pressure, sleep apnea, and other risk factors associated with atrial fibrillation can dramatically reduce the burden of the disease or eliminate it entirely.
American Society of Hypertension 2014 Annual Scientific Meeting
June 2nd 2014The American Society of Hypertension (ASH) is the largest US professional organization dedicated to eradicating hypertension and its consequences. The following study presentations were highlights of the organization's 29th annual meeting in New York City.
Study Finds Testosterone Therapy May Have Cardioprotective Benefits
Research presented at the 2014 annual meeting of the American Association of Clinical Endocrinologists indicates that testosterone replacement therapy may reduce the risk of cardiovascular events, contradicting two widely reported studies.
Cardiovascular Risk Factors Associated with Psoriatic Arthritis Complicate Treatment Decisions
May 28th 2014Patients with psoriatic arthritis may be at increased risk for cardiovascular disease, so physicians must carefully weigh the pros and cons of treatment with corticosteroids and other proatherogenic drugs.
Rosuvastatin Treatment Does Not Improve Lung Function in Patients with COPD
May 19th 2014Study results presented at the 2014 American Thoracic Society International Conference show that treatment with rosuvastatin reduces markers of inflammation in patients with COPD after 12 weeks, but is not associated with improvements in measures of lung function.
Simvastatin Does Not Affect Exacerbation Rates in High-Risk Patients with COPD
May 19th 2014Study results presented at the 2014 American Thoracic Society International Conference show that treatment with simvastatin did not decrease exacerbation rates or time to first exacerbation in patients with COPD.